Финам

      Cassava Sciences, Inc.

      Cassava Sciences, Inc.

      SAVA
      BATS
      Акции

      2,160 $

      0,010 $

      0,47%

      Обновлено 5 сент. 20:00

      1,150 $

      33,980 $

      Мин./макс. за год

      О компании

      Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.

      Капитализация

      104,35 млн $

      Кол-во акций

      48,31 млн

      Сектор

      Здравоохранение

      Отрасль

      Фармацевтика

      ISIN

      US14817C1071

      Размер лота

      100

      Ген. директор

      Mr. Remi Barbier

      Веб-сайт

      cassavasciences.com